clinical trial · NCT05767021
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company·phase3·completed·n = 172
Ulcerative ColitisUlcerative Colitis ChronicMirikizumabMirikizumab
brief summary
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
started
May 17, 2023
primary completion
Aug 9, 2024
completion
Apr 27, 2026
last updated
Jun 10, 2026
official title
A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol